Traumatic Brain Injury (TBI) Pipeline Insights, 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 6, 2018--The “Traumatic Brain Injury(TBI) - Pipeline Insights, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
‘Traumatic Brain Injury (TBI) - Pipeline Insights, 2018’ report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Traumatic Brain Injury (TBI) - Pipeline Insight, 2018 development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. Traumatic Brain Injury (TBI) - Pipeline Insights, 2018 Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Traumatic Brain Injury (TBI) - Pipeline Insights, 2018
4. Comparative Analysis
5. Products in Clinical StageProduct Description Research and Development Product Development Activities
6. Products in Pre-Clinical and Discovery StageProduct Description Research and Development Product Development Activities
7. Therapeutic AssessmentAssessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type
8. Inactive ProductsProduct Description Research and Development Product Development Activities
Companies MentionedVasopharm GmbH Stemedica Cell Technologies Neuren Pharmaceuticals NeuroVive Pharmaceutical SanBio Remedy Pharmaceuticals Mapreg Cellvation, Inc ProNeurogen Cognosci Inc.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gkpq68/traumatic_brain?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180906005954/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/06/2018 05:09 PM/DISC: 09/06/2018 05:09 PM